Deletion of Abcg2 Has Differential Effects on Excretion and Pharmacokinetics of Probe Substrates in Rats

This study was designed to characterize breast cancer resistance protein (Bcrp) knockout Abcg2(−/−) rats and assess the effect of ATP-binding cassette subfamily G member 2 (Abcg2) deletion on the excretion and pharmacokinetic properties of probe substrates. Deletion of the target gene in the Abcg2(−/−) rats was confirmed, whereas gene expression was unaffected for most of the other transporters and metabolizing enzymes. Biliary excretion of nitrofurantoin, sulfasalazine, and compound A [2-(5-methoxy-2-((2-methyl-1,3-benzothiazol-6-yl)amino)-4-pyridinyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one] accounted for 1.5, 48, and 48% of the dose in the Abcg2(+/+) rats, respectively, whereas it was decreased by 70 to 90% in the Abcg2(−/−) rats. Urinary excretion of nitrofurantoin, a significant elimination pathway, was unaffected in the Abcg2(−/−) rats, whereas renal clearance of sulfasalazine, a minor elimination pathway, was reduced by >90%. Urinary excretion of compound A was minimal. Systemic clearance in the Abcg2(−/−) rats decreased 22, 43 (p < 0.05), and 57%, respectively, for nitrofurantoin, sulfasalazine, and compound A administered at 1 mg/kg and 27% for compound A administered at 5 mg/kg. Oral absorption of nitrofurantoin, a compound with high aqueous solubility and good permeability, was not limited by Bcrp. In contrast, the absence of Bcrp led to a 33- and 11-fold increase in oral exposure of sulfasalazine and compound A, respectively. These data show that Bcrp plays a crucial role in biliary excretion of these probe substrates and has differential effects on systemic clearance and oral absorption in rats depending on clearance mechanisms and compound properties. The Abcg2(−/−) rat is a useful model for understanding the role of Bcrp in elimination and oral absorption.

[1]  J. W. Higgins,et al.  Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 Knockout Rats Using Loperamide, Paclitaxel, Sulfasalazine, and Carboxydichlorofluorescein Pharmacokinetics , 2012, Drug Metabolism and Disposition.

[2]  K. Maeda,et al.  Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP , 2012, British journal of pharmacology.

[3]  Lixia Jin,et al.  Effect of Culture Time on the Basal Expression Levels of Drug Transporters in Sandwich-Cultured Primary Rat Hepatocytes , 2011, Drug Metabolism and Disposition.

[4]  Tudor I. Oprea,et al.  BDDCS Applied to Over 900 Drugs , 2011, The AAPS Journal.

[5]  Suzanne Skolnik,et al.  Attenuation of Intestinal Absorption by Major Efflux Transporters: Quantitative Tools and Strategies Using a Caco-2 Model , 2011, Drug Metabolism and Disposition.

[6]  Wolfgang Löscher,et al.  Differences in the expression of endogenous efflux transporters in MDR1‐transfected versus wildtype cell lines affect P‐glycoprotein mediated drug transport , 2010, British journal of pharmacology.

[7]  A. S. Gross,et al.  Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. , 2010, Journal of pharmaceutical sciences.

[8]  April Chen,et al.  Relationship between Passive Permeability, Efflux, and Predictability of Clearance from In Vitro Metabolic Intrinsic Clearance , 2010, Drug Metabolism and Disposition.

[9]  A. Kalgutkar,et al.  N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a "chemical knock-out equivalent" to assess the impact of efflux transporters on oral drug absorption in the rat. , 2009, Journal of pharmaceutical sciences.

[10]  Y. Lai,et al.  Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion , 2009, Expert opinion on drug metabolism & toxicology.

[11]  F. Pontén,et al.  Correlations between RNA and protein expression profiles in 23 human cell lines , 2009, BMC Genomics.

[12]  P. Neuvonen,et al.  ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2009, Clinical pharmacology and therapeutics.

[13]  E. Kis,et al.  Kinetic characterization of sulfasalazine transport by human ATP-binding cassette G2. , 2009, Biological & pharmaceutical bulletin.

[14]  T. Ishikawa,et al.  Major SNP (Q141K) Variant of Human ABC Transporter ABCG2 Undergoes Lysosomal and Proteasomal Degradations , 2009, Pharmaceutical Research.

[15]  S. Bates,et al.  ABCG2: a perspective. , 2009, Advanced drug delivery reviews.

[16]  K. Maeda,et al.  Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin , 2008, Drug Metabolism and Disposition.

[17]  A. S. Gross,et al.  The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects. , 2008, British journal of clinical pharmacology.

[18]  H. Kusuhara,et al.  Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans , 2008, Clinical pharmacology and therapeutics.

[19]  Joe Palandra,et al.  Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe , 2008, Pharmacogenetics and genomics.

[20]  K. Maeda,et al.  SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[21]  Eun-Young Kim,et al.  Identification and Functional Assessment of BCRP Polymorphisms in a Korean Population , 2007, Drug Metabolism And Disposition.

[22]  T. Ishikawa,et al.  Re‐evaluation and functional classification of non‐synonymous single nucleotide polymorphisms of the human ATP‐binding cassette transporter ABCG2 , 2007, Cancer science.

[23]  M. Hidalgo,et al.  Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. , 2006, Journal of the National Cancer Institute.

[24]  Robert W. Robey,et al.  Breast Cancer Resistance Protein , 2006 .

[25]  Ya-li Liu,et al.  Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[26]  T. Ishikawa,et al.  Functional Validation of the Genetic Polymorphisms of Human ATP-Binding Cassette (ABC) Transporter ABCG2: Identification of Alleles That Are Defective in Porphyrin Transport , 2006, Molecular Pharmacology.

[27]  T. Litman,et al.  Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. , 2006, Cancer letters.

[28]  J. Ware,et al.  Breast Cancer Resistance Protein (BCRP/ABCG2) is a Major Determinant of Sulfasalazine Absorption and Elimination in the Mouse , 2006, Molecular pharmaceutics.

[29]  J. Castle,et al.  Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[30]  K. Maeda,et al.  Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.

[31]  A. V. van Herwaarden,et al.  The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin , 2005, Molecular Pharmacology.

[32]  S. Bates,et al.  Single nucleotide polymorphisms modify the transporter activity of ABCG2 , 2005, Cancer Chemotherapy and Pharmacology.

[33]  Y. Sugiyama,et al.  Functional Analysis of SNPs Variants of BCRP/ABCG2 , 2004, Pharmaceutical Research.

[34]  H. Kotani,et al.  Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2 , 2004, International journal of cancer.

[35]  Stephen A. Wring,et al.  Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.

[36]  Y. Miki,et al.  C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. , 2002, Molecular cancer therapeutics.

[37]  M. Vijver,et al.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.

[38]  D. Meijer,et al.  Mrp2 is essential for estradiol‐17β(β‐D ‐glucuronide)–induced cholestasis in rats , 2000 .

[39]  T. Chang,et al.  Effect of androgen administration during puberty on hepatic CYP2C11, CYP3A, and CYP2A1 expression in adult female rats. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[40]  M. Neville,et al.  Active transport of nitrofurantoin across the mammary epithelium in vivo. , 1997, The Journal of pharmacology and experimental therapeutics.

[41]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[42]  B. Hoener,et al.  Nitrofurantoin disposition , 1981, Clinical pharmacology and therapeutics.

[43]  April Chen,et al.  from in vitro Metabolic Intrinsic Clearance , 2009 .

[44]  雄一 杉山,et al.  医薬品添加物のBreast Cancer Resistant Protein 阻害による経口薬物吸収改善 , 2006 .

[45]  Leslie Z. Benet,et al.  Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.

[46]  E. Schuetz,et al.  Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. , 2003, Pharmacogenetics.

[47]  Y. Miki,et al.  C 421 A Polymorphism in the Human Breast Cancer Resistance Protein Gene Is Associated with Low Expression of Q 141 K Protein and Low-Level Drug Resistance 1 , 2002 .

[48]  S. Bandiera,et al.  EFFECT OF ANDROGEN ADMINISTRATION DURING PUBERTY ON HEPATIC CYP 2 C 11 , CYP 3 A , AND CYP 2 A 1 EXPRESSION IN ADULT FEMALE RATS , 1998 .